ArticleBMC research notes2023

A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE).

Matthew Gumbleton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.